JEFFERIES 2016 HEALTHCARE CONFERENC

JEFFERIES 2016 HEALTHCARE CONFERENCE — DR. NEAL WALKER CONFIRMS THAT TOPICAL JAK INHIBITERS WILL BE TESTED (AND WORK!?) ON ANDROGENIC ALOPECIA PATIENTS
JUNE 8, 2016 ADMIN 288 COMMENTS
Update: Listening to the webcast again (yes it is still available), Dr. Neal Walker clearly states that while systemic JAK inhibitors did not work for androgenetic alopecia, topical JAK inhibitors did work for androgenetic alopecia (and not just for alopecia areata)! This is huge. Thanks to commentator “Bob Ross’s Hair” for typing out the exact quote below for us:

“We will be developing a topical JAK inhibitor for androgenetic alopecia, and the data on that is quite interesting in that they found that the systemic JAK inhibitor does not work for that particular indication, but the topical does, mainly as a function of the target being more superficial in the skin and not really accessible from a systemic circulation.”

The important Jefferies 2016 Healthcare Conference is going on in New York City as I am writing this post. It started five minutes ago (12pm EST — aka NYC — time). The CEO of Aclaris Therapeutics, Dr. Neal Walker, is presenting. You can view it live via registering here. Or from here.

The best part is that 19 slides are already available to view at the top of the ongoing webcast, and Dr. Walker just mentioned that they are now more confident about JAK inhibiters and will be developing a topical version for androgenic alopecia!! One more small leap for “nasa_rs”, but will it finally translate into one giant leap for mankind?

Slide numbers 16 and 17 mention androgenic alopecia. The key March 2016 acquisition of and partnership with Dr. Angela Christiano’s Vixen Pharmaceuticals (Columbia University IP) is what seems to have spurred the optimism behind developing and testing topical JAK inhibitors on androgenic alopecia patients. Slide 16 also mentions that they are working on next generation JAK inhibitors called “covalently bound highly selective JAK3 inhibitors.”

Note that those slides and the audio webcast presentation are both supposed to soon be available on Aclaris’ website, but will only remain there for several weeks.

結果 (中文) 1:

JEFFERIES 2016 HEALTHCARE CONFERENCE — DR. NEAL WALKER CONFIRMS THAT TOPICAL JAK INHIBITERS WILL BE TESTED (AND WORK!?) ON ANDROGENIC ALOPECIA PATIENTSJUNE 8, 2016 ADMIN 288 COMMENTSUpdate: Listening to the webcast again (yes it is still available), Dr. Neal Walker clearly states that while systemic JAK inhibitors did not work for androgenetic alopecia, topical JAK inhibitors did work for androgenetic alopecia (and not just for alopecia areata)! This is huge. Thanks to commentator “Bob Ross’s Hair” for typing out the exact quote below for us:“We will be developing a topical JAK inhibitor for androgenetic alopecia, and the data on that is quite interesting in that they found that the systemic JAK inhibitor does not work for that particular indication, but the topical does, mainly as a function of the target being more superficial in the skin and not really accessible from a systemic circulation.”The important Jefferies 2016 Healthcare Conference is going on in New York City as I am writing this post. It started five minutes ago (12pm EST — aka NYC — time). The CEO of Aclaris Therapeutics, Dr. Neal Walker, is presenting. You can view it live via registering here. Or from here.The best part is that 19 slides are already available to view at the top of the ongoing webcast, and Dr. Walker just mentioned that they are now more confident about JAK inhibiters and will be developing a topical version for androgenic alopecia!! One more small leap for “nasa_rs”, but will it finally translate into one giant leap for mankind?幻灯片编号 16 和 17 提到雄激素性脱发。关键的 2016 年 3 月收购和与博士安吉拉 · 克里斯蒂的泼妇制药 (哥伦比亚大学 IP) 的伙伴关系是什么似乎刺激了背后开发和测试局部 JAK 抑制剂对雄激素性脱发患者乐观。幻灯片 16 也提到他们正在研究下一代 JAK 抑制剂称为"共价键高度选择性 JAK3 抑制剂"。请注意，这些幻灯片和音频网络广播演示文稿都应该很快就可以在 Aclaris 的网站上，但将只在那里呆几个星期。

結果 (中文) 3:

杰夫里2016医疗保健会议-尼尔沃克博士证实，外用JAK抑制剂将测试（和工作！对雄激素性脱发患者吗？）2016年6月8日管理288评论更新：听广播了（是的它仍然是可用的），尼尔沃克博士明确指出，而全身的JAK抑制剂没有雄激素性脱发，雄激素性脱发的外用JAK抑制剂对所做的工作（不是斑秃）！这是巨大的。感谢评论员Bob罗斯的头发”输入了确切的报价低于我们：“我们将发展为雄激素性脱发的外用JAK抑制剂，和数据，是相当有趣的，他们发现全身JAK抑制剂并不针对特定的指示工作，但局部的，主要是在皮肤和不可从一个系统循环更浅的目标函数”。重要的杰夫里2016医疗保健会议将在纽约市，因为我写这篇文章。这是五分钟前开始的（美国东部时间12点-又名纽约时间）。aclaris疗法的首席执行官，尼尔博士沃克，呈现。您可以查看它的生活通过登记在这里。或从这里。最好的部分是，19张幻灯片已经可以在正在进行的网络直播上来看，和沃克博士刚才提到，他们现在对JAK抑制剂更自信，将发展为雄激素性脱发的外用版！一个小的飞跃！”nasa_rs”，但它会最终转化为人类的一大步？幻灯片编号16和17提到的雄激素性脱发。关键2016三月收购和伙伴关系与安吉拉博士克里斯的泼妇制药（哥伦比亚大学IP）是什么似乎已经刺激了乐观的发展和对雄激素性脱发患者检测局部JAK抑制剂的背后。幻灯片16还提到，他们正在研究下一代的JAK抑制剂称为“共价结合的高选择性JAK3抑制剂。”请注意，这些幻灯片和音频网络直播演讲都应该很快aclaris网站是可用的，但只会停留几个星期。